Details of the Drug Pharmacogenomic Perturbation Atlas

Propantheline Drug Info

Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)

Therapeutic Class

Antispasmodics

Cross-matching ID

PubChem CID

4934

ChEBI ID

CHEMBL8481

CAS Number

CAS 298-50-0

TTD Drug ID

D0V5ZZ

ACDINA Drug ID

D00563

General Information of Drug (ID: DM2EN6G)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Arachidonic acid metabolism	2.06	2.28e-2	48/61 (78.69%)	ALOX5;PLA2G2A;PLA2G4C;...
Linoleic acid metabolism	2.02	1.14e-2	21/29 (72.41%)	PLA2G2A;PLA2G4C;CYP2E1;...
Ribosome biogenesis in eukaryotes	2.00	7.61e-3	52/108 (48.15%)	RPP40;NHP2;NXT1;...
alpha-Linolenic acid metabolism	1.99	7.61e-3	17/25 (68%)	PLA2G2A;PLA2G4C;PLA2G5;...
Pentose and glucuronate interconversions	1.92	7.61e-3	17/34 (50%)	UGT2B15;AKR1B10;UGT2B17;...
Ribosome	1.91	6.35e-3	113/158 (71.52%)	RPS4Y1;MRPS16;MRPS2;...
Folate biosynthesis	1.89	8.70e-3	23/26 (88.46%)	GGH;AKR1B10;TPH1;...
Mismatch repair	1.88	7.61e-3	22/23 (95.65%)	RPA3;PCNA;RFC3;...
DNA replication	1.87	7.61e-3	34/36 (94.44%)	RPA3;PCNA;RFC3;...
Oxidative phosphorylation	1.83	1.14e-2	93/133 (69.92%)	COX5B;COX7A1;CYC1;...
Mineral absorption	1.81	1.11e-2	48/60 (80%)	MT1M;FTH1;SLC26A3;...
Steroid hormone biosynthesis	1.80	1.14e-2	43/61 (70.49%)	HSD17B6;HSD17B2;HSD11B1;...
Systemic lupus erythematosus	1.78	1.29e-2	45/135 (33.33%)	C1QB;C3;C9;...
Ferroptosis	1.77	1.20e-2	36/41 (87.8%)	FTH1;SAT1;SLC39A14;...
RNA transport	1.73	2.03e-2	128/186 (68.82%)	EIF1AY;SEH1L;RPP40;...
N-Glycan biosynthesis	1.72	1.90e-2	38/50 (76%)	STT3A;ALG8;MGAT4A;...
Nicotine addiction	1.69	2.24e-2	32/40 (80%)	SLC17A7;GRIA2;GRIA1;...
Mannose type O-glycan biosynthesis	1.69	2.16e-2	14/23 (60.87%)	FKTN;POMT1;FUT9;...
Bile secretion	1.67	2.32e-2	68/90 (75.56%)	ABCC4;CA2;GNAS;...
Metabolism of xenobiotics by cytochrome P450	1.65	2.86e-2	49/77 (63.64%)	HSD11B1;UGT2B15;HPGDS;...
Non-alcoholic fatty liver disease	1.62	3.84e-2	126/155 (81.29%)	IRS2;CXCL8;COX5B;...
Diabetic cardiomyopathy	1.60	4.15e-2	162/203 (79.8%)	CYBB;COX5B;COX7A1;...
Parkinson disease	1.59	4.40e-2	176/249 (70.68%)	COX5B;GNAS;CYCS;...
Amyotrophic lateral sclerosis	1.58	4.57e-2	267/364 (73.35%)	COX5B;CYCS;PFN2;...
Pathogenic Escherichia coli infection	-1.61	4.63e-2	152/197 (77.16%)	CASP9;SEC24B;F2R;...
Primary immunodeficiency	-1.63	4.19e-2	33/38 (86.84%)	LCK;ADA;TAP2;...
Histidine metabolism	-1.64	4.17e-2	16/22 (72.73%)	HAL;AOC1;ALDH3A2;...
Platelet activation	-1.65	4.01e-2	106/124 (85.48%)	FGG;ITGA2;ACTB;...
TNF signaling pathway	-1.66	3.64e-2	103/112 (91.96%)	ATF2;TNF;CREB5;...
Fatty acid elongation	-1.66	3.80e-2	19/27 (70.37%)	PPT1;ELOVL1;ECHS1;...
C-type lectin receptor signaling pathway	-1.67	3.75e-2	93/104 (89.42%)	MAPK9;MAPK11;MAPKAPK2;...
ErbB signaling pathway	-1.67	3.38e-2	79/85 (92.94%)	MTOR;MYC;NRG1;...
Mitophagy	-1.70	2.68e-2	56/68 (82.35%)	RHOT2;BECN1;ATF4;...
Yersinia infection	-1.70	2.82e-2	120/137 (87.59%)	CRKL;ACTB;IFNB1;...
Biosynthesis of unsaturated fatty acids	-1.71	2.65e-2	21/27 (77.78%)	ELOVL2;SCD;ELOVL4;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.71	2.66e-2	62/70 (88.57%)	PAK1;CXCR1;ATP6V0C;...
T cell receptor signaling pathway	-1.72	2.33e-2	93/104 (89.42%)	TEC;MAP2K2;CD3E;...
Adherens junction	-1.72	2.47e-2	63/71 (88.73%)	PTPRM;PTPN6;ACTB;...
Melanogenesis	-1.73	2.48e-2	74/101 (73.27%)	EP300;MC1R;FZD7;...
Inositol phosphate metabolism	-1.73	2.57e-2	66/73 (90.41%)	PLCH2;INPP5A;TPI1;...
GnRH signaling pathway	-1.74	2.67e-2	80/93 (86.02%)	ADCY6;MAP2K4;ADCY3;...
Bladder cancer	-1.74	2.80e-2	40/41 (97.56%)	RB1;DAPK3;MAP2K1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.75	2.62e-2	79/89 (88.76%)	MAP2K2;CD3E;RPS6KB1;...
Renal cell carcinoma	-1.75	2.88e-2	68/69 (98.55%)	EGLN2;PAK1;BRAF;...
Salmonella infection	-1.77	2.93e-2	198/249 (79.52%)	MYC;DCTN2;CYFIP2;...
Endocrine and other factor-regulated calcium reabsorpti...	-1.81	2.40e-2	49/53 (92.45%)	ADCY6;KLK1;FXYD2;...
Axon guidance	-1.87	1.54e-2	151/182 (82.97%)	PARD6A;PARD3;LIMK1;...
Parathyroid hormone synthesis, secretion and action	-1.87	1.80e-2	98/106 (92.45%)	ARRB1;BRAF;MEF2A;...
Steroid biosynthesis	-1.94	9.59e-3	19/20 (95%)	SQLE;HSD17B7;MSMO1;...
Estrogen signaling pathway	-1.95	5.99e-3	119/137 (86.86%)	ATF2;GNAI1;ADCY6;...
Central carbon metabolism in cancer	-1.96	7.99e-3	67/70 (95.71%)	PFKM;SIRT3;PFKP;...
Proteoglycans in cancer	-2.00	5.99e-3	172/205 (83.9%)	MAPK11;PRKACB;GRB2;...
Phosphatidylinositol signaling system	-2.08	1.20e-2	82/97 (84.54%)	PIK3C3;MTMR1;PIK3C2B;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H